Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
3 hedge funds and large institutions have $19.3M invested in Plus Therapeutics in 2015 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
158% more capital invested
Capital invested by funds: $7.5M → $19.3M (+$11.8M)
25% less funds holding
Funds holding: 4 → 3 (-1)
57% less call options, than puts
Call options by funds: $16K | Put options by funds: $37K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.19M |
| 2 |
GCM
Goldman Capital Management
New York
|
-$204K |
| 3 |
D.E. Shaw & Co
New York
|
-$87K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$73K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61K |
PSTV Hedge Fund Activity: Q1 2015 in Review
3 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2015, worth a combined $19.3M — up 158% from $7.5M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PSTV and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, exiting entirely with an estimated $2.19M sold.
- 3 institutional investors held Plus Therapeutics (PSTV) as of Q1 2015, down from 4 in Q4 2014.
- Funds reported $19.3M of Plus Therapeutics stock for Q1 2015, up 158% quarter-over-quarter.
- 0 funds opened new Plus Therapeutics positions in Q1 2015 and 1 closed out, a net change of -1 holder.
- The largest Plus Therapeutics seller in Q1 2015 was Sabby Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q1 2015.